BGLC
BioNexus Gene Lab CorpCompany Information
- Company Name
- BioNexus Gene Lab Corp
- CIK
- CIK0001737523
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- BGLC: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 8071
- SIC Description
- Services-Medical Laboratories
- Ticker
- BGLC
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 116
- Shares outstanding
- 2,417,314
- Ownership
- 0.00%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -7.64%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 2 | 1 | 2 | 1 | 2 | - | 2 | - | - | - | - | - | ||||||
| Cash | - | - | - | - | - | - | - | - | - | 2 | 3 | 5 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Cash Equivalents At Carrying Value | - | - | - | - | - | 1 | 2 | 2 | 2 | - | 3 | - | ||||||
| Deposits Assets | - | - | - | - | - | 3 | 3 | 2 | 3 | 3 | 3 | 1 | ||||||
| Deposits Assets Current | 2 | 3 | 2 | 2 | 2 | - | 3 | - | - | - | - | - | ||||||
| Accounts Receivable Net | - | - | 1 | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 1 | 2 | 2 | - | 1 | - | - | - | - | - | ||||||
| Other Receivables Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Assets Noncurrent | 4 | 4 | 4 | 2 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | ||||||
| Other Assets Current | 1 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Income Taxes Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Inventory Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Finance Lease Right Of Use Asset | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | ||||||
| Other Investments | - | - | - | - | - | - | - | 2 | 2 | 2 | 2 | 2 | ||||||
| Equity Securities Fv Ni Current And Noncurrent | - | - | - | - | - | 1 | 1 | - | - | - | 2 | - | ||||||
| Equity Method Investments | 2 | 2 | 2 | 0 | 1 | - | 1 | - | - | - | - | - | ||||||
| Assets | 9 | 9 | 9 | 8 | 9 | 9 | 10 | 11 | 11 | 11 | 11 | 11 | ||||||
| Accounts Payable Current | - | - | - | - | - | 1 | 2 | 1 | 1 | 1 | 1 | 2 | ||||||
| Accounts Payable Trade Current | 0 | 0 | 0 | 0 | 1 | - | 2 | - | - | - | - | - | ||||||
| Other Accounts Payable And Accrued Liabilities | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Finance Lease Liability Current | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Customer Advances Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | ||||||
| Taxes Payable Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Finance Lease Liability Noncurrent | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Commitments And Contingencies | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Common Stock Value | 20 | 20 | 20 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | ||||||
| Additional Paid In Capital | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 8 | 8 | 9 | 7 | 8 | 8 | 8 | 9 | 10 | 9 | 10 | 9 | ||||||
| Retained Earnings Accumulated Deficit | -7 | -7 | -6 | -5 | -5 | -4 | -3 | -3 | -2 | -2 | -2 | -2 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -0 | -1 | -1 | -1 | -1 | ||||||
| Liabilities And Stockholders Equity | 9 | 9 | 9 | 8 | 9 | 9 | 10 | 11 | 11 | 11 | 11 | 11 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Shares Outstanding | 2 | 2 | 2 | 2 | 2 | 18 | 2 | 18 | 18 | 18 | 18 | 18 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deposit Assets | 1 | 2 | 2 | 2 | 2 | 2 | 1 | - | - | - | 1 | - | ||||||
| Allowance For Doubtful Accounts Receivable Current | 1 | 1 | 1 | 1 | 0 | 1 | 1 | - | - | - | 1 | - | ||||||
| Other Inventory In Transit | - | - | 0 | 0 | 0 | - | 0 | - | - | - | 0 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBioNexus Gene Lab Corp (BGLC) — SEC Financial Statements & Analysis
BioNexus Gene Lab Corp (BGLC) is a services-medical laboratories company, incorporated in WY. BioNexus Gene Lab Corp trades on Nasdaq as: BGLC. BioNexus Gene Lab Corp (BGLC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, BioNexus Gene Lab Corp carries a market cap of $4.71M, a P/E ratio of -1.83x, a P/B ratio of 0.61x, a P/S ratio of 1.51x, an enterprise value of $2.37M, and an EV/EBITDA multiple of -0.97x. On profitability, it posts a gross margin of 12.34%, an operating margin of -81.82%, a net margin of -82.36%, a Return on Equity (ROE) of -33.66%, a Return on Assets (ROA) of -28.38%, and a Return on Invested Capital (ROIC) of -43.81%. Per share, it reports EPS of $-1.07, diluted EPS of $-1.07, free cash flow per share of $-0.35, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -67.27% year-over-year, net income growth of -12.21% year-over-year, and EPS growth of -34.75% year-over-year. On the balance sheet, it maintains a current ratio of 6.08x, a quick ratio of 5.28x, working capital of $4.13M, a debt-to-equity ratio of 0.12x, a debt ratio of 0.11, an interest coverage ratio of -481.76x, free cash flow of $-853.60K (TTM), and net debt of $-2.34M. Figures sourced from SEC EDGAR.
- Market Cap
- $4.71M
- P/E TTM
- -1.83x
- EPS TTM
- $-1.07
- P/B TTM
- 0.61x
- ROE TTM
- -33.66%
- ROA TTM
- -28.38%
- Debt To Equity
- 0.12x
- Free Cash Flow TTM
- $-853.60K
- Net Revenue TTM Growth 1Y
- -67.27%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BioNexus Gene Lab Corp in?
BioNexus Gene Lab Corp (BGLC) operates in the Services-Medical Laboratories industry.
What exchange does BGLC trade on?
BioNexus Gene Lab Corp (BGLC) trades on the Nasdaq.
Where is BioNexus Gene Lab Corp incorporated?
BioNexus Gene Lab Corp is incorporated in WY.
When was BioNexus Gene Lab Corp (BGLC)'s most recent SEC filing?
BioNexus Gene Lab Corp (BGLC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is BGLC's market cap?
BioNexus Gene Lab Corp (BGLC) has a market capitalization of $4.71M as of 2026-06-30.
What is BGLC's EPS (earnings per share)?
BioNexus Gene Lab Corp (BGLC)'s trailing twelve month EPS is $-1.07 as of 2026-06-30.
What is BGLC's ROE (return on equity)?
BioNexus Gene Lab Corp (BGLC)'s trailing twelve month Return on Equity (ROE) is -33.66% as of 2026-06-30.
What is BGLC's ROA (return on assets)?
BioNexus Gene Lab Corp (BGLC)'s trailing twelve month Return on Assets (ROA) is -28.38% as of 2026-06-30.
What is BGLC's ROIC (return on invested capital)?
BioNexus Gene Lab Corp (BGLC)'s trailing twelve month Return on Invested Capital (ROIC) is -43.81% as of 2026-06-30.
What is BGLC's EV/EBITDA?
BioNexus Gene Lab Corp (BGLC)'s trailing twelve month EV/EBITDA is -0.97x as of 2026-06-30.